In a major relief for cardiac patients, the Bangladesh government has significantly reduced the maximum retail prices (MRP) of 10 coronary stents from leading global manufacturers, including Abbott, Boston Scientific, and Medtronic.
The revised pricing follows recommendations from a specialist advisory committee and a comprehensive analysis of international and domestic market rates, the Ministry of Health and Family Welfare said in a notice issued on Monday.
The new MRPs include all applicable taxes, VAT, service charges, and a reasonable profit margin for manufacturers aiming to ensure transparency and affordability in cardiac care.
Sharp price cuts offer immediate relief
The price reductions are substantial, addressing long-standing concerns that stents in Bangladesh were significantly more expensive than in neighbouring countries like India.
Key price changes include:
- Resolute Onyx (Medtronic): From Tk 1,40,500 to Tk 90,000 (36% reduction)
- Synergy XID (Boston Scientific): From Tk 188,000 to Tk 100,000 (47% cut)
- Promus Elite (Boston Scientific): From Tk 79,000 to Tk 72,000
- Xience Prime (Abbott): From Tk 66,600 to Tk 50,000 (25% reduction)
- Onyx Trucor (Medtronic): From Tk 72,500 to Tk 50,000 (31% cut)
Several other models from Abbott and Boston Scientific have also seen notable price adjustments, bringing life-saving cardiac treatment within reach for more patients.
Strict rules to prevent overcharging
To ensure compliance, the Health Ministry has issued strict directives: The new price list must be prominently displayed in all hospitals, clinics, and medical supply outlets; hospitals and healthcare providers are prohibited from charging more than 5 per cent above the MRP as service fees for stent implantation procedures; authorities have ordered strict monitoring across the supply chain to prevent the sale of cardiovascular and neuro-implant devices above the approved prices.
The ministry has also warned of legal action against violators, urging regulatory bodies and district health officials to conduct regular inspections.
A step toward affordable healthcare
Cardiovascular diseases remain the leading cause of death in Bangladesh, with thousands requiring stent placements each year. High device costs have long been a barrier to timely treatment, especially for low- and middle-income families.
With these revisions, the government aims to reduce out-of-pocket expenses and curb medical inflation in the private healthcare sector.
Health officials say the move reflects a broader commitment to equitable, affordable, and transparent healthcare — ensuring that no patient is denied critical treatment due to cost.
As one cardiologist in Dhaka put it: “This isn’t just about lowering prices — it’s about saving lives.”